Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function occurring in people with diabetes mellitus. Diabetic nephropathy is the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD), globally. Diabetic nephropathy is also defined by elevated urine albumin excretion or reduced glomerular filtration rate (GFR), or both. It is a serious complication that occurs in 20-40% of all diabetic patients.
Diabetic nephropathy is usually diagnosed during routine testing, which is a part of the diabetes management. Routine test used for diagnosis of diabetic nephropathy include urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR) and other special tests such as imaging tests (CT scanning, MRI) and Kidney biopsy.
Treatments of diabetic nephropathy are very necessary for patients. The first step in treating diabetic nephropathy is to treat and control diabetes and high blood pressure (hypertension). This includes diet, lifestyle changes, exercise, prescription medications, blood pressure control medicine, blood sugar control medicine, G-Protein Coupled Receptors (GPCR), and antioxidant inflammation modulators medicine. Furthermore, kidney dialysis, transplant, and symptom management treatment are also used for advanced diabetic kidney diseases. The diabetic nephropathy market is growing at rapid rate. Major factors driving growth of the diabetic nephropathy market include increase in geriatric population suffering from diabetes, increase in diabetic population, and rise in incidences of various kidney diseases. For instance, according to the Journal of Nutrition and Metabolism, in a survey at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, the incidence rate of diabetic nephropathy was 14 (95% CI 10.8-17.7) cases per 10,000 patients. In addition, 63 (13.6%) diabetes mellitus (DM) patients developed diabetic nephropathy. Type 2 DM patients who had coronary heart diseases and anemia were at higher hazard of developing diabetic nephropathy. Hence, such factors propel the market growth.
For instance, according to the National Diabetes Statistics Latest Report, 37.3 million people had diabetes (11.3% of the US population) in which 28.7 million people, including 28.5 million adults were diagnosed and 8.5 million people (23.0% of adults are undiagnosed) were undiagnosed in the U.S from 2017 to 2020.
Moreover, surge in diabetes and chronic kidney diseases leads to increase in number of diabetic nephropathies, which further require anti-diabetic nephropathy medicines, thus propelling adoption of anti-diabetic nephropathy medicine. Angiotensin-converting enzyme inhibitors have become more popular among products of diabetic nephropathy. Type-2 diabetes is the most trending diabetic nephropathy that draws attention of customers, fueling growth of the diabetic nephropathy market. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, AstraZeneca Plc. got approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.
However, unfavorable reimbursements as well as complications such as the market growth is limited by stricter regulatory standards and lengthy drug approval times. The market growth of the diabetic nephropathy is also restrained, owing to lack of comprehensive therapeutic therapy for diabetic nephropathy.
Furthermore, healthcare business is predicted to witness growth, owing to rise in prevalence of diabetes and obesity, increase in R&D investments in drug discovery & development, and rise in awareness regarding diabetes and kidney-related disorders. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
The diabetic nephropathy market is segmented on the basis of drug class, type, distribution channel, and region. On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor, and others. By type, the market is segregated into type-1 diabetes and type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug stores & retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)
Major players profiled in the report are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi.
Diabetic nephropathy is usually diagnosed during routine testing, which is a part of the diabetes management. Routine test used for diagnosis of diabetic nephropathy include urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR) and other special tests such as imaging tests (CT scanning, MRI) and Kidney biopsy.
Treatments of diabetic nephropathy are very necessary for patients. The first step in treating diabetic nephropathy is to treat and control diabetes and high blood pressure (hypertension). This includes diet, lifestyle changes, exercise, prescription medications, blood pressure control medicine, blood sugar control medicine, G-Protein Coupled Receptors (GPCR), and antioxidant inflammation modulators medicine. Furthermore, kidney dialysis, transplant, and symptom management treatment are also used for advanced diabetic kidney diseases. The diabetic nephropathy market is growing at rapid rate. Major factors driving growth of the diabetic nephropathy market include increase in geriatric population suffering from diabetes, increase in diabetic population, and rise in incidences of various kidney diseases. For instance, according to the Journal of Nutrition and Metabolism, in a survey at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, the incidence rate of diabetic nephropathy was 14 (95% CI 10.8-17.7) cases per 10,000 patients. In addition, 63 (13.6%) diabetes mellitus (DM) patients developed diabetic nephropathy. Type 2 DM patients who had coronary heart diseases and anemia were at higher hazard of developing diabetic nephropathy. Hence, such factors propel the market growth.
For instance, according to the National Diabetes Statistics Latest Report, 37.3 million people had diabetes (11.3% of the US population) in which 28.7 million people, including 28.5 million adults were diagnosed and 8.5 million people (23.0% of adults are undiagnosed) were undiagnosed in the U.S from 2017 to 2020.
Moreover, surge in diabetes and chronic kidney diseases leads to increase in number of diabetic nephropathies, which further require anti-diabetic nephropathy medicines, thus propelling adoption of anti-diabetic nephropathy medicine. Angiotensin-converting enzyme inhibitors have become more popular among products of diabetic nephropathy. Type-2 diabetes is the most trending diabetic nephropathy that draws attention of customers, fueling growth of the diabetic nephropathy market. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, AstraZeneca Plc. got approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.
However, unfavorable reimbursements as well as complications such as the market growth is limited by stricter regulatory standards and lengthy drug approval times. The market growth of the diabetic nephropathy is also restrained, owing to lack of comprehensive therapeutic therapy for diabetic nephropathy.
Furthermore, healthcare business is predicted to witness growth, owing to rise in prevalence of diabetes and obesity, increase in R&D investments in drug discovery & development, and rise in awareness regarding diabetes and kidney-related disorders. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
The diabetic nephropathy market is segmented on the basis of drug class, type, distribution channel, and region. On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor, and others. By type, the market is segregated into type-1 diabetes and type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug stores & retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)
Major players profiled in the report are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Distribution Channel
- Hospital Pharmacy
- Online Providers
- Drug Stores and Retail Pharmacy
By Drugs Class
- Angiotensin-converting Enzyme Inhibitors
- Angiotensin Receptor Blockers
- Calcium Channel Blocker
- Diuretics
- Renin Inhibitor
- Others
By Type
- Type-1 Diabetes
- Type-2 Diabetes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Bayer AG
- Abbott Laboratories
- Astrazenica Plc
- Eli Lilly and Company
- Pfizer Inc.
- Sanofi
- Novartis AG
- Merck & Co
- AbbVie Inc.
- Reata Pharmaceuticals
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS
CHAPTER 5: DIABETIC NEPHROPATHY MARKET, BY TYPE
CHAPTER 6: DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: DIABETIC NEPHROPATHY MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to this report, the diabetic nephropathy market was valued at $1.9 billion in 2021, and is estimated to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.The diabetic nephropathy market is expected to reach $3.33 billion by 2031. Diabetic nephropathy is the metabolic disorder in which the body has high sugar levels for prolonged period. Diabetes is of two types i. e., type-1 and type-2. Diabetic nephropathy is a medical condition in which diabetes affect kidney and causes chronic kidney diseases and kidney disorders. Diabetic nephropathy is one of the most significant complications, in terms of mortality and morbidity for patients with diabetes. It affects the ability of kidneys to do their usual work of removing waste products and extra fluid from body. The best way to prevent or delay diabetic nephropathy is by maintaining a healthy lifestyle and adequately managing your diabetes and high blood pressure. Kidney disease may progress to kidney failure, also called end-stage kidney disease. Kidney failure is a life-threatening condition. At this stage, treatment options are dialysis or a kidney transplant.Hypertension or high blood pressure and high cholesterol is a complication of diabetes that is believed to contribute directly to diabetic nephropathy. Therefore, anti-hypertensive drug and anti-hyperlipidemic drug is used to treat diabetic kidney diseases.
Growth of the diabetic nephropathy market is majorly driven by rise in geriatric population, surge in number of patients suffering from diabetes, chronic renal disease, atherosclerosis, and hypertension. Globally, the diabetic nephropathy market is witnessing significant growth, owing to increase in prevalence of diabetes and obesity in different regions of the world. In addition, rise in R&D investments in drug discovery and development and rise in awareness regarding diabetes and kidney-related disorders.
For instance, according to latest reports of the Indian Council of Medical Research, there were around 150% increment in diabetes cases in India in 2021. For instance, according to the International Diabetes Federation (IDF) Atlas Tenth edition 2021, approximately 537 million adults (20-79 years) are living with diabetes. More than 1.2 million children and adolescents (0-19 years) are living with type 1 diabetes, 541 million adults are at increased risk of developing type 2 diabetes, and 1 in 6 live births (21 million) are affected by diabetes during pregnancy.
For instance, according to the 9th edition of International Diabetes Federation, 463 million people are currently affected by diabetes globally, and it is expected to increase to 642 million by 2040.
Thus, above-mentioned factors are anticipated to fuel adoption of medicinal products against diabetic nephropathy disease. Furthermore, the market is highly competitive in nature, with major players focusing on creating awareness regarding diabetic nephropathy. Major players in the diabetic nephropathy market host exhibition and seminars to display and promote use of diabetic nephropathy for diverse medical applications.
In addition, discovery and development; launch of various products; and strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, in 2021, ASTRAZENECA got the approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.
However, the sales of diabetic nephropathy medicine have witnessed hindrances, owing to the strict government regulations on the quality of ingredient and excipients that are used in it. . Strict regulatory rules regarding selling and lengthy drug approval times also hamper the market growth.
On the contrary, surge in healthcare investments in public as well as private sectors, increase in patient population, and unmet medical demands in developing economies in mostly countries are anticipated to open new avenues for expansion of the diabetic nephropathy market during the forecast period.
By drug class type, the angiotensin-converting enzyme inhibitors segment was the highest revenue contributor to the market, with $567.95 million in 2021, owing to rise in number of temporary as well as permanent chronic heart disease, heart attack, hypertension, and diabetic nephropathy. The diuretics segment is expected to witness highest CAGR of 7.4% during the forecast period, owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones, and diabetic nephropathy.
On the basis of types, the type-2 diabetes segment generated maximum revenue in 2021, accounting for $1.46 billion, owing to surge in diabetes cases and increase in awareness and diagnosis of diabetic nephropathy. The type-2 diabetes segment is also expected to witness highest CAGR of 6.4% during the forecast period.
On the basis of distribution channel, the drug stores & retail pharmacy segment was the highest revenue contributor to the market, with $992.24 million in 2021, and is estimated to reach $1.83 billion by 2031, with a CAGR of 6.3%. The hospital pharmacy segment is estimated to reach $946.30 million by 2031, at a significant CAGR of 4.6% during the forecast period, owing to increase in population suffering from diabetes and geriatric population. Depending on region, North America generated maximum revenue in 2021, accounting for $807.50 million, owing to increase in number of patient admissions and chronic kidney diseases. Asia-Pacific is expected to witness highest CAGR of 7.3% during the forecast period, owing to surge in number of diabetic nephropathy cases, chronic heart disease cases, and increase in prevalence of hypertension.
Key Findings of the Study
By drug class type, the angiotensin-converting enzyme inhibitors segment held the largest share in the diabetic nephropathy market in 2021.By type, the type-2 diabetes segment held the largest share in the diabetic nephropathy market in 2021, and is expected to remain dominant during the forecast period.
On the basis of distribution channel, the drug stores & retail pharmacy segment held the largest market share in 2021.
On the basis of region, the hospitals segment held the largest market share in 2021, and is expected to remain dominant during the forecast period.
Companies Mentioned
- Bayer AG
- Abbott Laboratories
- Astrazenica Plc
- Eli Lilly and Company
- Pfizer Inc.
- Sanofi
- Novartis AG
- Merck & Co
- AbbVie Inc.
- Reata Pharmaceuticals
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
